BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Zhen Xu, Pingping Hu, Dong Fang, Lingna Ni, Jianzhong Xu. Electrostatic explanation of D1228V/H/N-induced c-Met resistance and sensitivity to type I and type II kinase inhibitors in targeted gastric cancer therapyJournal of Molecular Modeling 2019; 25(1) doi: 10.1007/s00894-018-3893-3
2
Jung-Soo Pyo, Guhyun Kang, Hyunjin Cho. Clinicopathological Significance and Diagnostic Accuracy of c-MET Expression by Immunohistochemistry in Gastric Cancer: A Meta-AnalysisJournal of Gastric Cancer 2016; 16(3): 141 doi: 10.5230/jgc.2016.16.3.141
3
Neelam Khetpal, Saeed Ali, Ranjeet Kumar, Mamoon Ur Rashid, Sarfraz Ahmad. Role of Tyrosine Kinases in Gastrointestinal Malignancies2018; : 29 doi: 10.1007/978-981-13-1486-5_3
4
JM Serpeloni, AFL Specian, DL Ribeiro, LM Benício, HL Nunes, LP Franchi, CQ Rocha, W Vilegas, EA Varanda, IMS Cólus. Fridericia platyphylla (Cham.) L.G. Lohmann root extract exerts cytotoxic and antiproliferative effects on gastric tumor cells and downregulates BCL-XL, BIRC5, and MET genesHuman & Experimental Toxicology 2019; : 096032711988826 doi: 10.1177/0960327119888261
5
Aaron C. Tan, David L. Chan, Wasek Faisal, Nick Pavlakis. New drug developments in metastatic gastric cancerTherapeutic Advances in Gastroenterology 2018; 11: 175628481880807 doi: 10.1177/1756284818808072
6
Rachel Sin-Yu Choi, Wing Yin Xenia Lai, Lok Ting Claire Lee, Wing Lam Christa Wong, Xiao Meng Pei, Hin Fung Tsang, Joel Johnson Leung, William Chi Shing Cho, Man Kee Maggie Chu, Elaine Yue Ling Wong, Sze Chuen Cesar Wong. Current and future molecular diagnostics of gastric cancerExpert Review of Molecular Diagnostics 2019; 19(10): 863 doi: 10.1080/14737159.2019.1660645
7
Mikito Inokuchi, Hideaki Murase, Sho Otsuki, Tatsuyuki Kawano, Kazuyuki Kojima. Different clinical significance of FGFR1–4 expression between diffuse-type and intestinal-type gastric cancerWorld Journal of Surgical Oncology 2017; 15(1) doi: 10.1186/s12957-016-1081-4
8
Bianca Della Croce Vieira Cota, Karine Sampaio Lima, André Márcio Murad, Marcelo Antônio Pascoal Xavier, Mônica Maria Demas Álvares Cabral, Luiz Gonzaga Vaz Coelho. Expression of the c-MET, HGF and VEGF biomarkers in intestinal and diffuse gastric cancer in the Brazilian population: a pilot study for the standardization of the quantitative PCR techniqueApplied Cancer Research 2017; 37(1) doi: 10.1186/s41241-017-0029-5
9
Ranjeet Kumar, Akriti Gupta Jain, Mamoon Ur Rashid, Saeed Ali, Neelam Khetpal, Ishtiaq Hussain, Sarfraz Ahmad. Role of Tyrosine Kinases in Gastrointestinal Malignancies2018; : 1 doi: 10.1007/978-981-13-1486-5_1
10
Chrysovalantou Mihailidou, Michalis V. Karamouzis, Dimitrios Schizas, Athanasios G. Papavassiliou. Co-targeting c-Met and DNA double-strand breaks (DSBs): Therapeutic strategies in BRCA-mutated gastric carcinomasBiochimie 2017; 142: 135 doi: 10.1016/j.biochi.2017.09.001
11
Henrique Duarte, Daniela Freitas, Catarina Gomes, Joana Gomes, Ana Magalhães, Celso Reis. Mucin-Type O-Glycosylation in Gastric CarcinogenesisBiomolecules 2016; 6(3): 33 doi: 10.3390/biom6030033
12
Mihaela Chivu-Economescu, Lilia Matei, Laura G Necula, Denisa L Dragu, Coralia Bleotu, Carmen C Diaconu. New therapeutic options opened by the molecular classification of gastric cancerWorld Journal of Gastroenterology 2018; 24(18): 1942-1961 doi: 10.3748/wjg.v24.i18.1942
13
Li-Ming Gao, Fang Wang, Yue Zheng, Zhan-Zhao Fu, Lei Zheng, Lan-Lan Chen. Roles of Fibroblast Activation Protein and Hepatocyte Growth Factor Expressions in Angiogenesis and Metastasis of Gastric CancerPathology & Oncology Research 2019; 25(1): 369 doi: 10.1007/s12253-017-0359-3
14
Wei-Zhong Sheng, Yu-Sheng Chen, Chuan-Tao Tu, Juan He, Bo Zhang, Wei-Dong Gao. <i>ANGPTL2</i> expression in gastric cancer tissues and cells and its biological behaviorWorld Journal of Gastroenterology 2016; 22(47): 10364-10370 doi: 10.3748/wjg.v22.i47.10364
15
Bo Shen, Feixiang Wu, Jiazhou Ye, Rong Liang, Ruping Wang, Ruoying Yu, Xue Wu, Yang W Shao, Jifeng Feng. Crizotinib-resistant MET mutations in gastric cancer patients are sensitive to type II tyrosine kinase inhibitorsFuture Oncology 2019; 15(22): 2585 doi: 10.2217/fon-2019-0140